Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Thomas James Doyle, Senior Vice President of Finance & Accounting at Kura Oncology Inc . (NASDAQ:KURA), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Doyle sold a total of 4,949 shares of Kura Oncology common stock on January 28, 2025. The shares were sold at an average price of $7.8719, resulting in a total transaction value of approximately $38,958.
Following these transactions, Doyle holds 88,193 shares directly. Additionally, he maintains an indirect ownership of 500 shares through his spouse’s 401(k) account. The sales were made to cover taxes associated with the vesting of restricted stock units (RSUs) received by Doyle on various dates. With the company’s next earnings report due on February 20, 2025, investors tracking insider activity can access comprehensive valuation metrics and 10+ additional ProTips through InvestingPro’s detailed research reports.
In other recent news, Kura Oncology has seen a flurry of activity. The company secured a new headquarters in San Diego, signing a lease agreement with HCP Life Science REIT, Inc. The new location will house Kura’s principal executive offices, research and development facilities, and laboratories.
Additionally, Kura Oncology has experienced significant changes in its executive team, with the departure of Chief Medical (TASE:PMCN) Officer, Stephen Dale, due to personal health challenges. In response to this departure, the company has appointed Mollie Leoni as the new Chief Medical Officer and Francis Burrows as the new Chief Scientific Officer.
In financial news, Stifel, a financial services firm, adjusted its outlook on Kura Oncology, reducing the price target to $11.00 from the previous $18.00, while maintaining a Hold rating on the stock. This adjustment follows recent developments within the company, including a partnership agreement related to ziftomenib, a treatment for acute myeloid leukemia.
Kura Oncology also announced an expansion to its stock option plan, reserving an additional 1.9 million shares of common stock for the 2023 Inducement Option Plan. This move suggests the company’s intent to attract top talent and expand its workforce.
These recent developments highlight Kura Oncology’s continued commitment to advancing its pipeline of oncology treatments and strategic efforts to strengthen its position in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.